<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03881683</url>
  </required_header>
  <id_info>
    <org_study_id>2018-A03113-52</org_study_id>
    <nct_id>NCT03881683</nct_id>
  </id_info>
  <brief_title>Determination of the Feasibility of Tumoural Somatic Mutations Detection in Blood of Patients With Ovarian Cancer</brief_title>
  <acronym>BOVARY Pilot</acronym>
  <official_title>Determination of the Feasibility of Tumoural Somatic Mutations Detection in Blood of Patients With Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de Lorraine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Cancérologie de Lorraine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      BOVARY-Pilot is a monocentric prospective transversal pilot study with a total duration of 6&#xD;
      months. The purpose of this study is to determine the feasibility of detecting somatic tumor&#xD;
      mutations in the blood of patients with ovarian cancer in order to determine whether a blood&#xD;
      test can replace a tissue biopsy to prescribe a personalized treatment. The method will&#xD;
      consist of a single blood sample during the patient's visit and prior to the establishment of&#xD;
      any newly diagnosed cancer treatment. The concordance of somatic mutations (SNV) found in&#xD;
      tissue and in cell-free DNA (cfDNA) extracted from blood will then be compared&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 21, 2020</start_date>
  <completion_date type="Actual">February 19, 2021</completion_date>
  <primary_completion_date type="Actual">February 19, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concordance between DNA extracted from tumour tissue and cfDNA extracted from plasma (SNV, indels)</measure>
    <time_frame>1 day (samples will be analyzed in batch at the end of inclusions)</time_frame>
    <description>Number of patients with detected punctual somatic mutations (SNVs and indels of BRCA1/2 and genes involved in HRD) concordance between DNA extracted from tumour tissue and cfDNA extracted from plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concordance between DNA extracted from tumour tissue and cfDNA extracted from plasma (large rearrangements, LOH, CNV)</measure>
    <time_frame>1 day (samples will be analyzed in batch at the end of inclusions)</time_frame>
    <description>Number of patients with detected genomic alterations (large rearrangements, LOH and CNV of BRCA1/2 and genes involved in HRD) concordance between DNA extracted from tumour tissue and cfDNA extracted from plasma</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>HRD and BRCA mutations</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>HRD and BRCA mutations</intervention_name>
    <description>Compare BRCA1/2 and HRD genes mutation detected from blood sample (20 ml) and biopsy</description>
    <arm_group_label>HRD and BRCA mutations</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Patient with stage III to IV non-treated high grade ovarian cancer or recurrent high&#xD;
             grade ovarian cancer&#xD;
&#xD;
          -  Adequate haemoglobin rate ≥ 9 g/dL&#xD;
&#xD;
          -  Patient who can benefit from an additional blood sample of 20ml. The total volume of&#xD;
             each sample meets with the indications of the Order in force establishing the list of&#xD;
             researches mentioned in 2 ° of Article L. 1121-1 of the Public Health Code.&#xD;
&#xD;
          -  Availability of tumor samples from biopsy or surgery&#xD;
&#xD;
          -  Patient affiliated to a social security scheme&#xD;
&#xD;
          -  Ability to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any concurrent severe and/or uncontrolled medical conditions which could compromise&#xD;
             participation in the study&#xD;
&#xD;
          -  Contraindication to a blood sample of 20 mL&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Ongoing treatment for the newly diagnosed cancer or the recurrence&#xD;
&#xD;
          -  Patient pre-treated with poly-ADP-ribose-polymérase-1 (PARP) Inhibitors&#xD;
&#xD;
          -  Patient under guardianship or curatorship or deprived of liberty.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GAVOILLE CELINE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de Lorraine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>HARLE ALEXANDRE, PhD pharmaD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut de Cancérologie de Lorraine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut de Cancerologie de Lorraine</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54506</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 6, 2019</study_first_submitted>
  <study_first_submitted_qc>March 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BRCA 1/2 genes</keyword>
  <keyword>Circulating Tumor DNA/blood*</keyword>
  <keyword>somatic tumor mutations</keyword>
  <keyword>HRD genes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

